A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) Read More

Genotype-guided Personalised Fluoropyrimidine Dosing: Feasibility and Implementation Read More

Lignocaine Infusion in Colorectal Cancer Patient Immune Cells (LICPIC Study) Read More

This is an open-label, randomised, prospective, multi-centre registry-based trial evaluating the impact of delivering all active cytotoxic agents during initial systemic therapy, by way of an alternating treatment schedule versus standard of care, on outcomes in treatment-naïve mCRC. Read More

RoLaCaRT-1 compares the use of robotic surgery with laparoscopic surgery for the surgical treatment of right-sided colon cancer. Read More

An organoid sensitivity testing driven umbrella study for patients with chemorefractory metastatic colorectal cancer. Read More

PALliative oEsOphageal cancer chemoradioimmunotherapy (PALEO): A multicentre Phase II Clinical Trial Read More

Neoadjuvant Immune-Chemo-Radiotherapy in operable oesophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab – a Trial assessing feasibility and preliminary Efficacy Read More

Can Oxaliplatin dose reduction and neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer? A phase II randomised study. Read More

mFOLFIRINOX And STEreotactic body Radiotherapy (SBRT) for Pancreatic cancer with high-risk and Locally Advanced disease (MASTERPLAN): a multicentre, randomised phase II study. Read More

Prospective Study of ‘Watch and Wait’ Strategy in Patients with Rectal Cancer who have Developed a Clinical Complete Response with concurrent Chemo‐radiotherapy: RENO trial (REctal cancer No Operation) Read More

This study aims to demonstrate that a ctDNA informed approach to chemotherapy, following surgery for localised pancreatic cancer, could lead to a reduction in the proportion of patients with detectable ctDNA after completion of treatment compared to standard of care. Read More

The purpose of the DYNAMIC-III study is to determine that a chemotherapy decision based on the presence or absence of circulating tumour DNA after surgery for stage III colorectal cancer, will be more effective than standard of care treatment as measured by how many patients remain cancer free at 3 years. Read More

The aim of NABNEC is to determine the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with the current standard chemotherapy treatment plan (carboplatin plus etoposide) for advanced gastrointestinal neuroendocrine carcinomas (NECs). Read More

This randomised phase II trial aims to evaluate the effect of simvastatin (SIM) on efficacy and toxicity of pCRT in rectal cancer patients, and on systemic and local inflammatory responses. Read More